4 more proliferative, migratory and angiogenic than eutopic MSCs obtained from the endometrial lining of same patient or control MSCs from healthy individuals without endometriosis [9, 10] . Hence, endometriosis has been described as an end result of an ectopic stem cell differentiation process. On the other hand, eutopic MSCs could be considered as the best suited vehicle for treating endometrial disorders, as they are specific to the endometrium.
It is advantageous to use the same tissue stem cells as they would survive and function better than MSCs from any other sources. In addition, it is possible that eutopic MSCs may take a lesser time-lag in adjusting to the endometrium microenvironment than MSCs of other origins, and therefore, enhancing its therapeutic efficacy.
MSCs have been used in a number of trials for corrective therapies using gene modification techniques [12, 13] . MSC-mediated gene therapies possess certain unique advantages over direct gene transfers into the body; these include homing towards the site of injury, ease of handling in culture conditions, weak immunogenicity and suitability for gene transduction [14] . A recent study from our group has indicated that MSC mediated gene therapy could be applied to endometriosis [15] . The focus of this review is to highlight the efficacy and benefits of using residing eutopic MSC populations as novel gene therapy tools for endometriosis.
Endometrial stem cells: a promising therapeutic tool
The last decade has witnessed great progress in the endometrial stem cell research. Their presence in the human uterine tissue was first reported by Chan et al in 2004 [16] .
Subsequently, a number of studies reported the presence of resident MSC populations in both human and mouse uteri [17 -19] . An ever increasing number of FDA-approved clinical trials that aim to treat a number of pathologies reflect the rise in demand for an ideal source of adult stem cells for therapeutic purposes. Endometrium, which undergoes nearly 400 5 cycles of complete regeneration and differentiation during each menstrual cycle, is thus an attractive and convenient source for regenerating adult stem cell populations [20] .
Human endometrium regenerates on a cyclic basis from underlying candidate endometrial stem/progenitors [21] . In vivo reports suggest the ability of endometrial stem/progenitor cells to develop human endometrium on subcutaneous injection in NOD-SCID mice [22, 23] . It has been reported that the morphological and functional features of human endometrium could be reproduced in murine models using xenotransplantation techniques [24] . When human endometrial cells (epithelial, stromal, endothelial and immune cells) were xenotransplanted under the kidney capsule in severely immunodeficient mice, regeneration of a functional endometrial tissue that mimics normal endometrium was observed. The engrafted human tissue formed chimeric functional blood vessels within the mouse endothelium validating the idea that human endothelial cells/progenitors derived from the endometrium can migrate, invade and form vasculature in host tissues of different species [24] . Endometrial Stem Cells (EnSCs) are broadly classified into epithelial progenitor cells, MSCs, endothelial progenitor cells and endometrial side population (SP) cells [21] . These stem cells are the likely precursors of endometrial epithelial/stromal fibroblast cells [21] . The epithelial and stromal stem cell-like precursors have high proliferative potential and they undergo up to 30-32 population doublings before senescence, whereas endometrial non-stem epithelial and stromal cells undergo approximately 12 population doublings [9, 17] . Like their counterparts, bone marrow stem cells (BMSCs) [25] , EnSCs could be identified using specific set of markers, such as CD9, CD13, CD14, CD29, CD31, CD44, CD73, CD90, CD105, CD117, CD133 and CD146. They lack in expression for STRO-1, CD31 and CD34.
Among the different populations that are identified as endometrial stem/progenitor cells, endometrial side population (SP) cells [26] and MSCs [20] have drawn much attention in recent years. A number of studies have suggested that EnSCs possess side population 6 phenotype and are characterized by their ability to exclude the DNA-binding dye Hoechst 33343 owing to presence of ATP-binding cassette transporter proteins [22, 27, 28] .
Endometrial SP cells are identified both in the epithelial and stromal compartment of the endometrium and endometriotic tissues [26, 28, 29] . Freshly isolated and in vitro cultures of EnSCs have been reported to comprise up to 5% of SP cells [28, 30, 31] . Endometrial SP cells, both from the stromal and epithelial compartments, displayed genotypic, phenotypic and functional features of somatic stem cells [22] . However, their therapeutic potential is yet to be explored further.
Gargett et al identified the presence of regenerating MSC populations in the culture of freshly isolated endometrial stromal cells [17] . The study demonstrated that endometrial stromal cells exhibit MSC properties and co-express perivascular cell markers, such as CD146 and platelet-derived growth factor-receptor β (PDGF-Rβ). CD146 + PDGFR + EnSCs can differentiate into mesenchymal lineages, such as adipocytes, smooth muscle cells, chondrocytes and osteoblasts in vitro [17] . EnSCs can be grown extensively and maintained in culture for up to 40 passages [17] . Under specific conditions, these cells can differentiate into various lineages such as chondrogenic, osteogenic, adipogenic, angiogenic and myogenic [9, 10, 17] . In addition to the above reports, a couple of studies showed that bone marrowderived stem cells (BMDSCs) contribute to the repair and regeneration of endometrial tissues [32, 33] . CD133(+) BMDSCs, when injected into a murine model of Asherman syndrome (AS), showed cell engraftment and proliferation around endometrial vessels [33] . The studies suggest that the residing endometrial stem cell populations could be BMDSCs that had migrated under stimulating conditions and colonised in the endometrial tissue.
The therapeutic usefulness of EnSCs has been described by a number of in vitro [34, 35] and in vivo studies [36, 37] , and a few clinical trials have also been reported [38 -40] . In vivo 7 studies reported their successful use in the treatment of Duchenne muscular dystrophy (DMD), cardiac, neural and bone regeneration, pancreatic differentiation, tissue engineering and glioma models [21] . Successful clinical trials include their use in multiple sclerosis, ischemic cardiomyopathy and DMD [21] .
Endometrial Stem Cells: are they flexible tools for gene therapy?
Gene therapy holds an exciting promise for the treatment of numerous disorders; a couple of animal studies and in vitro experiments have indicated its application in endometriosis [5, 15, 41, 42] . Potential targets for gene therapy of endometriosis include genes related to angiogenesis, hormonal balance and inflammatory mediators [43] . The advantages of using gene therapy for endometriosis include site-specific action of therapeutic agents and avoidance of adverse side effects of conventional estrogen therapy and disease recurrence.
Gene therapy trials for endometriosis are mentioned later in the article. Globally, nearly 600
clinical trials have been registered that use MSCs for the treatment of a wide range of immune and degenerative disorders [44] . The clonogenic, immunogenic and differentiation potentials of MSCs offer the flexibility of these cells for use in such interventions [9, 18] .
Endometrial (eutopic) MSCs serve as a powerful gene therapy tool due to their characteristic anti-inflammatory, immunosuppressive and tissue reparative properties [9] . Like MSCs from other sources, eutopic MSCs have also been extensively characterized for their immunogenic properties [9, 10, 18] . We have earlier explored the immunosuppressive and immunomodulatory features of eutopic and ectopic MSCs using peripheral blood mononuclear cells (PBMCs) [9] . In vitro co-culture experiments involving human eutopic MSCs and mitogen-activated PBMCs resulted in approximately 50% reduction in the proliferation of PBMCs, whereas the same was observed to be compromised in ectopic
MSCs. We reported the immunosuppressive properties of eutopic MSCs and their feasibility in utilizing for cell transplantation studies [9] . Recently, we explored the therapeutic potential 8 of eutopic MSCs in devising a targeted anti-angiogenic therapy for endometriosis [15] .
Women with endometriosis exhibit enhanced angiogenesis at the ectopic lesion sites [10, 15] .
Hence, we focused on targeting angiogenesis in order to curb disease progression in endometriosis. Eutopic MSCs isolated from human endometrial biopsy specimens were transduced with adenoviral vectors expressing the anti-angiogenic factor, soluble truncated VEGF receptor-1, sFLT-1(Ad-sflt-1). In Ad-sflt-1 vector, sFlt-1 (soluble fms related tyrosine (Fig. 1 ).
An effective anti-angiogenic agent should be able to inhibit angiogenesis both in the newly developing/nascent lesions as well as established lesions. Usually, in experimental endometriosis, anti-angiogenic reagents were administered in three different ways; (1) pretreatment of the study models before endometrial implantation; (2) at the time of transplantation of endometrial fragments; and (3) following lesion formation as a treatment strategy [45] . Nascent microvessels establish in the endometrioic lesion sites usually between 5 and 8 days of endometrial implantation [45] . In our study, anti-angiogenic therapy was administered two weeks following endometrial implantation [15] . This time period is sufficient for vascularisation necessary for lesion establishment in the animal.
Administration of four doses of 10 6 MSC-Adsflt1 following two weeks of lesion establishment resulted in a highly efficient anti-angiogenesis response; the disease progression was inhibited effectively without any notable sign of new lesion growth. The study envisaged that employing MSC-Adsflt-1 gene therapy would be most suitable for the abrogation of nascent ectopic lesions that may eventually help in reducing the chances of recurrence of the disease. Further studies in higher animal models employing new improved target specific vectors are required to fully assess this promising strategy in endometriosis care.
Vectors used in gene therapy of endometriosis: success stories
In order to maximize the therapeutic effects of gene therapy and minimize toxicity on nontarget tissues, specific vector designing/targeting strategies need to be implemented [46] . This can be achieved by using two major approaches; transductional targeting and/or transcriptional targeting. Transductional targeting enables selective delivery of the therapeutic gene at the target of interest. Transductional targeting of adenoviruses involves specific modifications in the adenovirus fibers, which includes attachment of targeting peptides, serotype knob switching or fiber replacements [47] . These modifications in the capsid proteins of adenovirus would help in routing its cell entry through receptors that are specifically expressed on pathological tissues [5] . In the transcriptional targeting approach, the vector may initiate non-specific gene transfer to a large number of cells; however, its transgene expression is restricted specifically to the target tissue [47] . This strategy uses tissue specific promoters that display preferential activity in the pathological tissues. An ideal tissue-specific promoter for transcriptional targeting could be defined by the selective display of "pathological tissue on" and "non-target tissue off" phenotype [5] .
Adenoviral and adeno-associated vectors are being widely used for gene therapy studies [46] .
The advantages of recombinant adenoviruses include their ease of propagation, limited pathogenicity and low mutagenesis potential in humans [5] . They are able to transfer the genetic material effectively in a wide spectrum of dividing and non-dividing cells [47] .
However, the wide tropism of adenoviruses is a major limitation, since it could lead to nonspecific gene transfer affecting non-target cells. This is due to the recognition of the coxsackie-adenovirus receptor (CAR), the cell surface receptor, by the C-terminal part of an adenovirus fiber protein, termed the knob [48] . CAR receptor is distributed widely over many cells and this poses a major drawback wherein the vector identifies even the non-target cells/tissues [48] . Hence, there is a need for a more specific viral vector in gene therapy based transplantation studies. Othman et al developed an advanced, conditionally replicative adenovirus expressing tissue-specific promoters such as heparanase (Ad-heparanase-luc) [5] .
These targeted adenoviruses encode luciferase reporter gene in the E1 region under the transcriptional control of the heparanase promoter. Heparanase is a heparan sulfate-specific glucuronidase that plays an important role in tumor cell metastasis. They cleave extracellular matrices and are found to be present in endometriosis tissues [49] . Use of Ad-heparanase-luc resulted in an efficient removal of primary endometriotic cells obtained from ovarian endometrioma lesions in vitro. These viral vectors were target-specific and did not impact on liver tissues adversely [5] .
Another tissue specific promoter that has been used for targeting endometriotic cells is secretory leukocyte protease inhibitor (SLPI), which is a potent inhibitor of leukocyte serine proteases that protects mucosal surfaces against injury associated with inflammation [5] .
The presence of transcripts of SLPI was detected in ovarian endometrioma, peritoneal endometriosis, and deep recto-vaginal endometriosis; it was absent in normal ovarian tissue or eutopic endometrium of healthy females [50] , suggesting that SLPI could be the likely promoter for transcriptional targeting. A comparative study, however, reported a higher activity for Ad-heparanse-luc vectors over Ad-SLPI-luc in endometriosis cells owing to its relatively lower activity in the liver tissues [5] . Ad-heparanse-luc exhibited an "endometriosis on, liver off" phenotype, hence, it was considered to be a promising vector for future endometriosis gene therapy trials [5] .
A few reports have shown therapeutic benefits of the recombinant adenoviral and adeno- Rein et al used conditionally replicative adenoviruses (CRADs), which replicate within and destroy target cells, but not normal cells, in the endometriosis models [52] . The viral replication was maintained under the control of VEGF promoter and in vitro studies showed induction of apoptosis in endometriotic cells. Intra-peritoneal administration of the vector, however, resulted in a reduced VEGF promoter activity in the liver as well as endometrium.
Subsequently, Paupoo et al demonstrated the promise of a modified CRAD, CRAD-S-pK7, with dual advantages of infection enhancement and promoter specificity [53] . Polylysine pK7 promoted the best infection enhancement of the adenoviruses whereas survivin promoter exhibited the highest activity in endometriotic cell lines. The CRAD-S-pK7 vector exhibited higher replication rates and cell-killing efficiencies in vitro [53] .
A suicide gene therapy approach, where an enzyme transforms a pro-drug into a toxic metabolite, has been used to target endometrial cells using adenoviral vectors [43] . Herpes simplex virus thymidine kinase (HSV-tk) transforms ganciclovir (GCV) into ganciclovir triphosphate, which is toxic for endometrial cells. Adenoviral vectors encoding the HSV-tk gene (AdTK) were delivered into human endometrial cells, which were further treated with GCV. This resulted in a significant level of induction of cell death. When administered into mouse models of endometriosis, AdTK significantly reduced the size of the endometriotic lesions [43] .
The role of P27 protein, an important cell cycle regulatory factor has been implicated in endometriosis pathogenesis [54] . P27 regulates cell cycle checkpoint at the G1 to S transition state in normal cells. Absence of P27 results in exaggerated proliferation of cells and their down-regulation has been reported in ovarian, endometrial and breast neoplasia [54] .
Endometriotic tissues have a dysregulated expression for cell cycle and inflammatory proteins and lower levels of p27 kip1 protein [55] . Cells isolated from endometriotic tissues also have lower levels of p27 kip1 compared to healthy endometrial cells [54] . A recent study demonstrated that gene therapy using Adp27 carrying the p27 kip1 coding gene (Adp27EGFP), restored the p27 kip1 expression, promoting a G1 cell cycle arrest and reduced cellular proliferation [55] . Similar studies targeting estrogen receptors, earlier described by Othman et al, yielded successful results using adenoviral vectors. In the in vitro system, transfer of the dominant negative estrogen receptor gene into human endometriotic cells resulted in the initiation of apoptosis [56] . 
Concerns yet to be addressed

